HealthPharma & Biotech
Genus plc

Genus sounds note of caution over African swine fever and trade disputes

"The successful launch of Sexcel, our innovative proprietary 21st century sexed semen product in September 2017, was a real highlight after many years of pioneering development"

Pigs in a pen
African Swine Fever was detected in China for the first time in August 2018

Investors turned bearish on animal genetics company Genus PLC (LON:GNS) after some cautious comments in its full-year results statement.

The company warned that the external environment for many of its customers is challenging because of trade disputes and the recent spread of African swine fever to China.

READ: Genus ordered to pay US$2mln after cow semen court case

Peel Hunt responded to the cautious outlook by adjusting its estimates for the current fiscal year by around 4% but left its fiscal 2020 estimates unchanged as it does not see the tricky conditions lasting for too long.

The broker left its 2,600p price target unchanged but downgraded the stock to ‘hold’ from ‘buy’; the shares currently trade at 2,598p, down 4.6% on the day.

Aside from the cautious outlook, this morning’s statement was generally a story of growth with revenue in the year to the end of June rising 2% (+6% in constant currency terms) to £470.3mln from £459.1mln the year before and adjusted profit before tax climbing 4% (+6%) to £58.5mln from £56.4mln the previous year.

The results were in line with management’s expectations.

Reflecting confidence in the future, the dividend was increased by 10% to 26p from 23.6p the previous year.

"Genus performed strongly in 2018, achieving our financial objectives and making good strategic progress,” said Karim Bitar, the chief executive officer of Genus.

Bitar said growth in the dairy and beef cattle business, ABS, was particularly strong, while it was another good year for PIC, the pigs business.

"The successful launch of Sexcel, our innovative proprietary 21st century sexed semen product in September 2017, was a real highlight after many years of pioneering development. It was very pleasing to hear from dairy farmers how the product performance is exceeding their expectations. The commencement of the strategic partnership with Møllevang in July 2018 will further strengthen and bring new opportunities to our PIC business,” Kitar said.

Short-term uncertainty​

Stockbroker Liberum left its rating at ‘hold’ and its target price at 2,400p, saying market swings have brought short-term caution but long-term opportunities.

Like Peel Hunt, it has revised the current year estimate for profit before tax down by 4% but unlike Peel Hunt, it has also trimmed 2% off next year’s forecast.

“Genus is confident in the future growth prospects for the business yet trade disputes, FX volatility and the recent outbreak of African Swine Fever in China bring short-term uncertainty. While the short-term market-led outlook is cautious, in the mid-term, this may bode well for Genus given it may increase the need for breeding stock,” the broker said.

Quick facts: Genus plc

Price: £28.50

Market: LSE
Market Cap: £18.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

1 hour, 55 minutes ago

3 min read